Theme this week
This week’s most immediate clinic signal is NUMELVI. FDA granted approval on February 25, 2026, and Merck expects spring 2026 launch for veterinary clinics and hospitals nationwide.1 2 Zoetis also announced a March 2 deal to buy Neogen’s animal genomics business, adding a strategic data and testing asset. 3 4
New to PULSE? Start here to get more out of PULSE intelligence briefs.
Executive takeaways
- NUMELVI is a top-priority clinic signal this week. Decide NUMELVI protocols for first purchase and refill ownership before anticipated spring availability and heavy dosing allergy season. FDA granted product approval on February 25, 2026, for control of pruritus associated with allergic dermatitis in dogs 6 months of age and older. 1
- Launch sequencing shapes who owns first-fill. Merck’s clinic-and-hospital launch language points to a short planning window for product education, stocking, and refill-routing decisions. Long-term clinic exclusivity has not been determined. 2
- Zoetis made the week’s clearest upstream capability move. Zoetis’s March 2, 2026, agreement to buy Neogen’s animal genomics business adds data, testing, and software capability that Zoetis says will support predictive insights and individualized care across livestock and companion animal species. 3 4
Signals
1: NUMELVI approval creates a near-term protocol review event
OBSERVED
FDA lists NUMELVI (atinvicitinib tablets) as approved on February 25, 2026 for the control of pruritus associated with allergic dermatitis in dogs 6 months of age and older. 1
Merck expects product availability to vet clinics and hospitals nationwide in spring 2026. 2
VIEWPOINT
This is a clinic-relevant pet Rx ordering/operating opportunity, not just a product launch. Practices should decide where NUMELVI fits in allergic-dermatitis care before spring availability brings heavy prescribing potential, product education, and Rx refill routing questions.
CONFIDENCE
High - the approval is in FDA’s primary record, and the near-term clinic launch timing is in Merck’s official release. The main uncertainty is uptake and protocol placement.
ACTIONS
Independent veterinary practices
- Before the next medical-operations meeting, have the chief DVM review approved indication and decide where NUMELVI fits in the practice's allergic-dermatitis protocol.
- While preparing for spring ordering, decide how the clinic wants to capture first-fill, and align technician and front-desk scripts to that choice. Establish staff-wide key messages supporting your vet clinic’s online store/home delivery and convenient auto-ship options for this chronic medication.
Corporate veterinary groups and clinic consolidators
- Put NUMELVI through formulary review this month and standardize eligibility, group product education, and refill-routing rules across sites.
- Ask regional medical leaders to collect early field questions so individual hospitals do not improvise policy.
Distributors, e-retail and home delivery providers
- Add NUMELVI to the launch watchlist now and track when listings, pack sizes, and fulfillment options appear outside clinic channels.
- Prepare service scripts that explain availability clearly and route prescribing questions back to the veterinarian.
Manufacturers and commercial operators
- Give field teams label-accurate comparison tools and avoid implying outcomes beyond the approved indication.
- Educate vet practices and staff on the benefits of promoting refill purchases through the clinic’s online store to win refill purchases and realizing the “lifetime value” of a pet with chronic allergies.
- Support account onboarding before spring availability with simple stocking, education, and refill-routing materials.
2: Merck names clinics and hospitals in the expected spring launch channel
OBSERVED
Merck says NUMELVI is expected to be available at veterinary clinics and hospitals nationwide in spring 2026. 2
FDA approved NUMELVI on February 25, 2026. 1
VIEWPOINT
History supports a short preparation window, not a proven clinic-first distribution strategy. Merck says NUMELVI is expected to be available at vet clinics and hospitals nationwide in spring 2026, however, no channel exclusivity or timing for broader pharmacy availability has been disclosed. 2 If broad clinic adoption and product pull-through sales lag, then practices may have a narrow window open to set first-purchase and refill expectations.
CONFIDENCE
Moderate - the channel statement is direct and official. The duration and commercial strength of any clinic-led initiation window are not yet disclosed.
ACTIONS
Independent veterinary practices
- Before the product arrives, decide who owns first-fill key messages, authorization handling, and refill-routing conversations for eligible patients.
- During every potential new patient visit, clearly state where the first-fill will be dispensed and how refills will be handled. Encourage auto-ship enrollment through practice’s online store/home delivery to improve compliance, help pet owners with Rx expense budgeting, and keep replenishment sales revenue in-house.
Corporate veterinary groups and clinic consolidators
- Add a temporary launch metric this quarter for first-fill retention and early refill leakage on new dermatitis starts.
- Standardize callback language so refill intent does not vary by location.
Distributors, e-retail and home delivery providers
- Monitor channel appearance weekly and be ready to support fulfillment once broader distribution opens.
- Train agents not to promise availability timing that the current public record does not support.
Manufacturers and commercial operators
- If clinic-led initiation is intentional, back it with clear ordering systems, availability, vet staff education, and refill-routing guidance.
- If broader rollout will follow quickly, share the sequence early to reduce channel confusion.
3: Zoetis agrees to buy Neogen’s animal genomics business
OBSERVED
Zoetis announced a definitive agreement to acquire Neogen’s animal genomics business for $160 million, subject to customary closing adjustments on March 2, 2026. 3
Zoetis says the acquisition expands its ability to deliver predictive insights and individualized care across major livestock and companion animal species. 3
Neogen says the business generated approximately $90 million in fiscal 2025 sales and serves livestock and companion animal industries. 4
VIEWPOINT
This is a strategic data and testing acquisition rather than a clinic workflow change. It matters because Zoetis says the asset expands predictive insights and individualized care across major livestock and companion animal species, yet no record to date shows a companion animal bundle, workflow integration, or pricing model.
CONFIDENCE
Moderate - buyer and seller both corroborate the transaction and asset scope.
ACTIONS
Independent veterinary practices
- Ask account reps this quarter how precision-animal-health tools may affect future companion animal offerings, pricing, or workflow.
- Keep diagnostic, data-sharing, and referral workflows documented so future bundled offers can be evaluated on your terms.
Corporate veterinary groups and clinic consolidators
- Add genomics and data-enabled tools to vendor scanning this quarter, especially where they could influence referral or preferred-care pathways.
- Have information technology, medical, and commercial leaders review any future companion animal workflow proposal together.
Distributors, e-retail and home delivery providers
- Watch for manufacturer offerings that begin to bundle therapeutics with data, testing, or predictive monitoring.
- Assess whether new data layers could influence where ongoing care decisions and refill intent are formed.
Manufacturers and commercial operators
- Treat data and genomics as commercial assets, not just commercial tools; and review your map of companion animal gaps now.
- Pressure-test where customers may start expecting integrated decision support rather than product-only selling.
Early watch items
1: Some new companion animal Rx launches may begin with clinic-led initiation
OBSERVED
FDA approved NUMELVI on February 25, 2026 for allergic-dermatitis pruritus control in dogs 6 months of age and older. 1
Merck says the product is expected to be available at veterinary clinics and hospitals nationwide in spring 2026. 2
SPECULATIVE ASSESSMENT
This may be an early sign of clinic-led initiation for some new companion animal prescription launches. One launch is not enough to establish a pattern which makes this an early watch item until additional launches show the same sequencing.
CONFIDENCE
Low - the launch evidence is real, but a broader pattern forecast rests on a single example.
WHAT WOULD CONFIRM THIS
- Newer companion animal Rx launches explicitly name clinics or hospitals as the initial availability channel.
- Broader retail or home-delivery availability appears later than clinic onboarding.
- Manufacturers add clinic-first ordering, starter, or refill-routing supports to launch plans.
WHAT WOULD RULE THIS OUT
- New launches continue to be channel-neutral from day one.
- External pharmacy/E-retail Rx availability appear at the same time as clinic launch.
HOW TO PREPARE NOW
- Independent veterinary practices: build a simple launch checklist now for new clinic-led products: protocol decision, stocking choice, counseling script, and refill-routing language.
- Corporate veterinary groups and clinic consolidators: create one temporary metric for first-fill retention on new launches.
- Distributors, e-retail and home delivery providers: monitor launch timing weekly and avoid promising availability too early.
- Manufacturers and commercial operators: Communicate explicit launch sequencing plan so channel partners are not guessing.
2: Companion animal genomics may move closer to commercial planning at large manufacturers
OBSERVED
Zoetis says its Neogen transaction will expand predictive insights and individualized care across major livestock and companion animal species. 3
Neogen says the sold business serves livestock and companion animal industries and generated about $90 million in fiscal 2025 sales. 4
SPECULATIVE ASSESSMENT
This may be an early sign that large manufacturers will bring more genomics and data tools into companion animal commercial planning. The transaction is real, but the current disclosures do not yet show a clinic-facing companion animal commercialization model.
CONFIDENCE
Low - the transaction is real, but the future companion animal commercial path remains largely undeclared.
WHAT WOULD CONFIRM THIS
- Zoetis later announces companion animal tools, diagnostics, or workflows tied to genomics.
- companion animal field teams begin using genomics or predictive insights in account narratives.
- Future disclosures connect this asset to companion animal care pathways or product bundles.
WHAT WOULD RULE THIS OUT
- The acquisition stays largely livestock focused.
- The business remains a back-end capability with little visible companion animal commercial use.
HOW TO PREPARE NOW
- Independent veterinary practices: keep vendor and workflow choices modular so new data-enabled offers can be evaluated, not absorbed by default.
- Corporate veterinary groups and clinic consolidators: add interoperability and data-governance questions to supplier reviews now.
- Distributors, e-retail and home delivery providers: track whether data-enabled offerings begin to influence refill or care-routing decisions.
- Manufacturers and commercial operators: map where companion animal customers may want integrated therapeutics, diagnostics, and data services.
Methodology and governance
This PULSE Edition covers developments posted or acted on from February 25, 2026 to March 4, 2026 using US Eastern Standard Time (EST).
Observed statements are anchored to public sources and attributed subscriber reports cited below. Viewpoints are PETMETRIX assessments that interpret commercial implications for operators. Early watch items are early hypotheses. They are not yet strong enough for a full Signal, and they include what would confirm or rule out the pattern.
PETMETRIX PULSE commercial intelligence is provided for informational use and to support lawful, independent business decisions. It is not legal, clinical, reimbursement, accounting, or financial advice. Route legal, clinical, reimbursement, accounting, and financial decisions to qualified advisers. Respect for the veterinary-client-patient relationship is mandatory.
Terms of Service | Privacy Policy | Methodology and Data Disclaimer
Glossary
Buy box: The default offer a shopper sees on an online marketplace; controlling it often affects conversion.
Confidence: PETMETRIX rating of the strength and consistency of a signal. It is expressed as High, Moderate, or Low and does not mean certainty.
Corroborated: Supported by more than one credible source type.
Effective price: The price a buyer pays after discounts, coupons, rebates, subscription savings, promotions, and shipping.
Observed: A statement anchored in an attributable source, for example a company announcement, regulator posting, publication, data release, or market report.
Pharmacy leakage: Prescriptions or refills that move away from the clinic into outside pharmacies, online pharmacies, or home delivery channels.
Speculative assessment: A forward-looking hypothesis based on early indicators, with criteria that would confirm or rule out the pattern.
Viewpoint: PETMETRIX interpretation of observed facts through a commercial lens.
References
- U.S. Food and Drug Administration. “Recent Animal Drug Approvals.” February 25, 2026. https://www.fda.gov/animal-veterinary/approved-animal-drug-products-green-book/recent-animal-drug-approvals ↩︎
- Merck & Co., Inc. “FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis.” February 25, 2026. https://www.merck.com/news/fda-approves-numelvi-atinvicitinib-tablets-for-dogs-from-merck-animal-health-the-first-and-only-second-generation-janus-kinase-jak-inhibitor-for-the-control-of-pruritus-associat/ ↩︎
- Zoetis. “Zoetis to Acquire Animal Genomics Business from Neogen®, Accelerating Precision Animal Health Innovation.” March 2, 2026. https://news.zoetis.com/press-releases/press-release-details/2026/Zoetis-to-Acquire-Animal-Genomics-Business-from-Neogen-Accelerating-Precision-Animal-Health-Innovation/default.aspx ↩︎
- Neogen Corporation. “Neogen Announces Sale of Genomics Business to Zoetis.” March 2, 2026. https://investors.neogen.com/news/news-details/2026/Neogen-Announces-Sale-of-Genomics-Business-to-Zoetis/default.aspx ↩︎
Quick Links
← PULSE Archive | Signup for PULSE (Free) | Methodology & Data Disclaimer